ML LABORATORIES, the USM-quoted company which is researching treatments for
Aids and kidney patients, is raising Pounds 15.8m through a 1-for-10 rights
issue of 2.49m shares at 650p apiece.
Proceeds will be used to fund construction of a manufacturing plant to
produce its glucose polymer for use in the treatment of patients suffering
from kidney failure.
The shares yesterday fell by 28p to 735p.
The rights issue is fully underwritten by Hoare Govett Corporate Finance who
together with Panmure Gordon are brokers to the issue.
ML's losses trebled to Pounds 460,000 in the year to September 30 compared
with a deficit of Pounds 116,000 last time.
